Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.

MLA

Halperin, Daniel M., et al. “Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.” JAMA Oncology, vol. 8, no. 6, June 2022, pp. 904–09. EBSCOhost, https://doi.org/10.1001/jamaoncol.2022.0212.

APA

Halperin, D. M., Liu, S., Dasari, A., Fogelman, D., Bhosale, P., Mahvash, A., Estrella, J. S., Rubin, L., Morani, A. C., Knafl, M., Overeem, T. A., Fu, S.-C., Solis, L. M., Parra Cuentas, E., Verma, A., Chen, H.-L., Gite, S., Subashchandrabose, P., Dervin, S., … Yao, J. C. (2022). Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncology, 8(6), 904–909. https://doi.org/10.1001/jamaoncol.2022.0212

Chicago

Halperin, Daniel M, Suyu Liu, Arvind Dasari, David Fogelman, Priya Bhosale, Armeen Mahvash, Jeannelyn S Estrella, et al. 2022. “Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.” JAMA Oncology 8 (6): 904–9. doi:10.1001/jamaoncol.2022.0212.